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Introduction
At time of writing, there were 5,729 citations on the topic of 
‘responders and non-responders’ in the PubMed database (http://
www.ncbi.nlm.nih.gov). This would suggest that the topic is of 
interest to many people, but in truth no studies have explored 
why some subjects respond to probiotic or prebiotic intervention 
and others do not. The issue is important for human and indeed 
experimental animal studies for two main reasons: (i) Would 
changing the design of the study result in more subjects respond-
ing to treatment, and thereby increase the clinical data showing 
that these interventions can provide added value to patient/ani-
mal care? (ii) If a subject does not respond what are the mecha-
nistic reasons?
The term responder refers primarily to a subject who reacts 
favorably to the therapy, but clearly there are degrees of respon-
siveness and different parameters by which the response could be 
measured. For example, in the one study pertaining to responders 
and non-responders to probiotic therapy, the primary measure-
ment of response was based upon the Crohn’s disease activ-
ity index and the International Organization for the Study of 
Inflammatory Bowel Disease score.1 The conclusion was that 
the scores were significantly reduced after therapy (255–136, 
p = 0.009; 3.5–2.1, p = 0.03, respectively), based upon six patients 
having a complete response, one a partial response and three not 
responding. If the primary measurement of response had been 
decreased or discontinuance of prednisone use, then one of the 
‘non-responders’ and the ‘partial responder’ would have been 
categorized as ‘responders,’ and four original responders would 
have been classified as ‘non-responders’. This case illustrates some 
of the issues involved in how response and lack of response to 
 probiotics is defined.
A second example derives from a study of HIV-positive men 
treated with anti-retroviral therapy plus a so-called probiotic. 
Although the primary outcome was not clear, diarrhea was com-
pletely resolved in 36% (10/28) subjects,2 raising the question 
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As with many clinical studies, trials using probiotics have 
shown clearly that some patients benefit from the treatment 
while others do not. For example if treatment with probiotics 
leads to 36% cure rate of diarrhea, why did the other 64% not 
have the same result? The issue is important for human and 
indeed experimental animal studies for two main reasons: 
(i) Would changing the design of the study result in more 
subjects responding to treatment? (ii) If a subject does not 
respond what are the mechanistic reasons? In order to tackle 
the issue of responders and non-responders to therapy, a 
workshop was held by the International Scientific Association 
for Probiotics and Prebiotics (ISAPP). The outcome was four 
recommendations.
(1) Clearly define the end goal: this could be supporting a 
health claim or having the highest clinical effect and impact.
(2) Design the study to maximize the chance of a positive 
response by identifying precise parameters and defining the 
level of response that will be tested.
(3) Base the selection of the intervention on scientific 
investigations: which strain(s) and/or product formulation 
should be used and why.
(4) Carefully select the study cohort: use biological or ge-
netic markers when available to stratify the patient population 
before enrollment and decide at what point intervention will 
provide the best outcome (for example, in acute phase of dis-
ease, or during remission, with or without use of pharmaceuti-
cal agents).
By following these recommendations and selecting an ap-
propriate primary outcome, it is hoped that clinical data will 
emerge in the future that expands our knowledge of which 
probiotics benefits which subjects and by what mechanism.
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body mass index, cholesterol levels, pre-diabetic markers, and 
other surrogate markers such as weight, glucose levels, and bile 
salt hydrolase. Precise stratification of the disease or health state 
of the enrolled subjects is critical.
Timing of the Intervention
The time at which an intervention can have a greater chance or 
being effective is important for several reasons. The multi-strain 
probiotic VSL#3 has been used to help patients stay in remis-
sion from mild pouchitis during maintenance treatment.7 In this 
open-label study, 16 (69%) of the 23 patients went into remission 
while 7 showed no change. Notably, the entrance criterion was 
mild pouchitis, and potentially had they chosen a more severe 
status fewer subjects would have responded. The intervention 
was timed for when the subjects were already in remission rather 
than when they were being treated for active disease. Although 
there are some mechanistic rationales for using probiotics to 
treat active colitis, such as normalizing epithelial ion transport 
function,8 until clinical studies are done, the effectiveness of this 
approach will not be known.
A randomized, placebo-controlled trial of 327 patients with 
quiescent UC treated with E. coli Nissle 1917 showed equivalence 
in relapse rate (34–36%) to treatment with mesalazine.9 This 
again illustrates that timing (quiescent phase of the disease) is 
important in conjunction with design (comparison with a drug), 
outcome (number of relapses) and an understanding of mecha-
nism (anti-inflammatory effect).
An argument has been made that probiotic use immediately 
after intestinal surgery or following relapse diagnosis, might 
help prevent or delay IBD recurrence.10 However, a study of 70 
Crohn’s disease patients showed that use of Lactobacillus johnsonii 
LA1 for 12 weeks following ileo-caecal resection, did not prevent 
early endoscopic recurrence.11 One explanation could be that not 
all probiotic strains are able to have an effect in this disease, as 
also shown by failure of L. rhamnosus GG along with standard 
drug therapy to prolong time to relapse in children with Crohn’s 
disease.12 Given the fact that probiotic effects are strain-specific, 
it is rather unlikely that we will ever be able to state that probiot-
ics (in general) are efficient in one or another disease. Rather, we 
should confine statements to the specific strain and product for 
which the effect has been shown.
Selecting the Best Probiotic  
Based on Mechanistic, Scientific Criteria
The selection of a probiotic that has the highest chance of response 
in the host is far from easy. A mechanistic understanding about 
the effect of the probiotic should be achieved. However, while in 
vitro experiments can help describe a strain, and animal mod-
els may suggest efficacy, only when the human studies are per-
formed can the definitive answer be obtained. Even then, phase 
one safety trials do not necessarily predict efficacy as has been 
found with recombinant Lactococcus lactis expressing human 
IL-10 which showed initial promise,13 but in phase two studies in 
Crohn patients has so far failed.
what happened to the other 64%? In fact, 15 of the remaining 
18 subjects had fewer stool passages per day (p < 0.05), which 
could be regarded as a response to therapy, albeit not the pri-
mary response. This illustrates how a response rate is influenced 
by the defined endpoint(s) of interest, as well as which is deemed 
to be most clinically relevant. This latter point is often dependent 
upon what the company making the product wants to claim in its 
regulatory documentation. In some countries, claiming that diar-
rhea is cured by a probiotic would be regarded as a drug claim, 
while reduction in stool frequency would not. Since probiotics 
and prebiotics are food additives and can also be medical thera-
pies, research in this arena presents unique challenges for the sci-
entific community.
Predicting the Outcome
It is sometimes possible to predict who will respond to a specific 
treatment and who is less likely to do so. This can be achieved 
if biomarkers for disease response are identified. For example, 
using a rat model of galactosamine-induced hepatitis, there are 
clearly responders and non-responders to this hepatitis-inducing 
agent. However, the presence of fecal galN-pyrazines in non-
responders, but not responders, allows the separation of the two 
groups by a fecal biomarker.3 In terms of probiotics, if a Crohn 
disease patient has defective nucleotide-binding oligomerization 
domain (Nod)2 receptors, it is likely that they would not respond 
to lactobacilli probiotic treatment.4 This should be investigated 
before a clinical study is performed to determine if any patients 
have Nod2 mutations and subject enrollment criteria modified 
appropriately. However, in the study cited above,1 no Nod2 sta-
tus was reported, and therefore its role in non-responses cannot 
be assessed.
Another issue is extent to which the disease being treated pro-
gresses or does not progress. Some HIV-infected patients respond 
to highly active antiretroviral therapy (HAART), while others 
do not. In the latter group, a study has shown that an increase 
in apoptotic CD8+ T cells and decrease in Treg cells is associated 
with this failure, and leads to progression of the disease to AIDS.5 
The implication is that a therapy, such as probiotic lactobacilli 
known to increase Treg cell numbers6 could help the efficacy of 
HAART. In terms of maximizing the response rate, in this case 
the difficulty comes from not easily identifying subjects prior to 
enrollment whose disease will progress and whose will not.
A practical problem comes when there is a 10% difference 
between results from active and placebo treatments. In the case 
of preventing diarrhea or respiratory infections, how do we find 
the 10% of subjects who did not get sick but were ‘exposed’ to the 
virus or pathogen? Without stringent assessment of all enrolled 
subjects, this is a difficult goal to achieve.
The actual condition being examined may also differ between 
countries, regions and subject populations. For example if setting 
up a study to determine if probiotics increase time to onset of 
diabetes, a US cohort might be obese ‘healthy’ children while in 
France these subjects may be not be defined as healthy. Thus, in 
order to optimize the usefulness of the study’s conclusions, the 
subjects would need to be defined by a range of factors including 
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potential exposure to carcinogens in the workplace affect the 
recurrence rate? Some of these confounders can be dealt with 
by sub-analysis of the clinical trial, as long as care was given in 
selecting a large enough study group, and some consideration 
was given to matching factors at enrolment. In addition, the 
trial should be designed to increase the chance of detecting an 
independent effect associated with the probiotic. For example, if 
the probiotic was shown to adhere to polyps and directly reduce 
their size or eradicate them, then the outcome of fewer or smaller 
polyps at follow-up or longer time to next occurrence of a polyp 
could more easily be attributed to the probiotic than to other 
confounders. The use of cluster models for clinical trials22 has 
many advantages including being better suited to account for 
confounders, even at the end of the trial through regression anal-
ysis. Clustered data are collected from subjects who are members 
of a group and who may be presumed, by virtue of the fact that 
they are members of that group, to have a greater similarity to 
those within the group than to individuals outside it.
Acquiring Relevant Data that Might Explain 
Differences between Responders 
and Non-Responders
To date, there are few reliable biomarkers available to help 
 measure the outcome of probiotic or prebiotic trials. Nevertheless, 
there are ways to gather volumes of data within which may be 
indicators of change associated with the therapy. For example, 
the gut microbiota of humans is highly individual, and composi-
tional differences might define who is a responder and who not. 
Sequencing analytical tools are now available to obtain a readout 
of the composition and semi-quantitative count of the microbi-
ota of the gut and vagina.23,24 With bar-coding sequencing tech-
niques insight can be provided such as presence of drug resistance 
mutations,25 and traced back to the samples. Likewise, multiplex 
immunological assays and genomic arrays can identify host fac-
tors that change as a result of exposure to the treatment.6,26 Such 
information can help answer questions such as what role do the 
microbiota and the functions of the microbiota, and what role do 
the host’s response to the microbes play in the eventual response 
or non-response to the therapy? The use of metabolomic analyses 
can be daunting given the requirement for expensive equipment 
and novel expertise. However, if accessible, it can provide valu-
able data, such as the use of Ion Cyclotron Resonance Fourier 
Transform Mass Spectrometry (ICR-FT/MS) to interpret the 
thousands of metabolites present in fecal samples from healthy 
individuals and those with Crohn disease.27 In twins, metabolites 
can be positively or negatively correlated to the disease phenotype 
(such as obese or lean) and to specific microbes recovered from 
the stool.28 The combined use of metabolomics and microbial 
genomics can reveal novel metabolites associated with disease 
and potentially useful for diagnosis and treatment. Detecting 
metabolites such as butyrate can on one hand correlate with a 
health benefit,29 and on the other hand suggest a potential adverse 
outcome.30
Lastly, the value of quality of life (QoL) and treatment 
 compliance assessments should be considered when acquiring 
One philosophy for selection of certain strains is whether they 
are naturally occurring in target site, and the predominant mem-
ber of that species. This is the rationale for selecting L. crispatus 
CTV05 for implantation into the vagina,14 albeit L. iners is argu-
ably more commonly found there.15 Another approach is to select 
a strain that has a set of characteristics deemed best suited for 
application to the target site. This was the reason for choosing 
L. rhamnosus GR-1 and L. reuteri RC-14 for improving vaginal 
health.16 This was perhaps fortuitous, given that in vitro data 
cannot fully predict in vivo utility.
If we were to take the same approach to improving intestinal 
health in patients with IBD, using a strain of Faecalibacterium 
prausnitzii could be worthwhile given that it can downregu-
late inflammation,17 and is an extremely common member of 
the healthy gut microbiota, and absent or in low counts in 
patients with colitis.18 A strain of this species has so far not been 
propagated for use in humans, and it may prove difficult to 
achieve given its anaerobic requirements. Nevertheless, if it was 
available, a key element of its application would be to use it in 
patients with depleted F. prausnitzii numbers in the gut, and to 
be able to detect the probiotic strain and its affect on inflamma-
tion after use. The latter is difficult given the accessibility of the 
sites where anti-inflammatory activity might occur, and that 
even if the strain was found associated with previously inflamed 
and now normal sites, it would still be difficult to prove cause 
and effect.
It has long been assumed that the probiotic strain(s) is respon-
sible directly for the clinical effect, but it is also feasible that the 
strain alters the micro-environment in such as way as to alter the 
microbiota, and this then indirectly changes the host’s disease 
status. In the multi-species oral cavity, inter-bacterial communi-
cation and cooperative interactions have been known for some 
time,19 yet no probiotic has so far been selected based upon its 
activity within a dynamic multi-species biofilm. Rather, multi-
ple strains of bacteria have been chosen, apparently at random, 
and put into a formulation that is used as a so-called probiotic. 
Unfortunately, these formulations have been created without 
evidence that the additional strains augment the effects of the 
single strain formulation, or more importantly, that the multiple 
constituents do not counteract each other’s activity. The repeated 
failure of products such as Ecologic 641,20,21 may be explained by 
this poor selection process.
Dealing with Confounders
Once a study cohort has been selected and a clinical trial design 
established using a well-documented probiotic, it is important to 
consider confounding factors that may or may not influence the 
host’s response. For example, if a probiotic has been selected that 
degrades certain carcinogens, downregulates chronic inflamma-
tion and affects apoptosis and there is a cancer patient cohort 
just having completed surgical removal of a tumor and chemo-
therapy, how will factors like family history and genetics play a 
role in recurrences? Similarly, how will previous history of the 
disease, body mass index, use of common prescription and OTC 
medications such as non-steroidal anti-inflammatory agents, and 
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to reduced use of pharmaceutical agents, longer time to disease 
recurrence, changes in bowel habits, up or downregulation of 
specific immunological or microbiologic parameters, or changes 
in other specific biomarkers.
(3) Base the selection of the intervention on scientific inves-
tigations: which strain(s) and/or product formulation should be 
used and why; can we expect and measure the same mechanism 
of action in humans; for example using Faecalibacterium praus-
nitzii because it can downregulate inflammation.
(4) Carefully select the study cohort, by using biologi-
cal or genetic markers to stratify the patient population before 
enrollment. For example inflammatory bowel disease patients 
(children, adults, Crohn disease or ulcerative colitis) whose 
F. prauznitzii levels are low; decide at what point intervention 
will provide the best outcome (for example in acute phase of dis-
ease, or during remission, with or without use of pharmaceutical 
agents); and try to obtain as much sample data as possible (micro-
biota sequencing, fecal water and blood metabolomics, immu-
nological parameters, subject parameters such as demographics, 
lifestyle or anthropometric variables, and quality of life question-
naire) so as to increase understanding of what happened and why.
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data about who responds to a treatment and how this response 
is perceived, as well as why no effect is detected. Relatively few 
probiotic clinical trials have used QoL tools, but one recent study 
of 120 subjects with ulcerative colitis showed changes in emo-
tional, bowel and social functioning with various treatments.31 
In the end, how the person feels is a major determinant of being 
a responder to treatment, but this depends on whether or not 
QoL is used to define “responder.” If QoL is mearused along 
with other data such as microbiota composition, dietary profile, 
anthropometrics, ethnicity, physical activity and other potential 
confounders, the findings can not only be better put into context, 
but they will allow a better understanding of how and why some 
subjects do or do not respond.
Recommendations
The workshop participants made the following four recommen-
dations with respect to increasing the number of subjects respond-
ing to the administration of probiotic and/or prebiotic use:
(1) Clearly define the end goal—this could be supporting a 
health claim or consumer benefit, or having the highest clinical 
effect and impact.
(2) Design the study to maximize the chance of a positive 
response by using clearly defined parameters for the level of 
response that will be tested: from quality of life or days off work, 
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